A study across five European countries
FDA-approved Insurance accepted $99/mo Home Delivery available Contrave combines two medications naltrexone, which blocks opioid receptors to reduce the reward response to food, and bupropion, an antidepressant that suppresses appetite and increases energy expenditure
In turn, the overall BW loss, defined as achieving 5% and 10% reduction, was similar between men and women
However, retatrutide remains investigational and is not yet approved in the UK or United States, with regulatory submission still pending and approval not anticipated before 2027 at the earliest
Improve digestion, energy, and nutrient absorptiondoctor-formulated
NICE guidance supports the use of GLP-1 receptor agonists for type 2 diabetes (NG28) when certain criteria are met, typically after other treatments have been tried